The Programming Language Scene in 2026 and the Positioning of RustIn the software development landscape of 2026, the Rust ...

JetBrains' Java and Kotlin by IntelliJ IDEA extension reaches release candidate for VS Code, Cursor, and Antigravity after a ...

The country’s pharmaceutical industry has grown big enough to shift from low-cost generics to developing new drugs, said three of the country’s major pharma companies, pointing to China’s rapid shift ...

Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home. Credit...Video by Harsha Vadlamani Supported by By Alex Travelli ...

If you take a patented, brand-name medication — a cancer biologic, an autoimmune drug, a specialty injection — the supply chain behind that drug is about to be permanently restructured, starting at 12 ...

Par Health has launched the first generic formulation of Janumet XR in 3 extended-release dosage strengths, offering a lower-cost alternative for glycemic control. Par Health announced the ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

A multiyear “tariff cliff” sets 0% through July 2028, then 100% for one year and 200% thereafter, explicitly tying penalties to failure to establish US manufacturing capacity. Sparse implementation ...

The most common prescription drugs you pick up at the pharmacy counter or fill via mail order will likely get more expensive under President Donald Trump's plan to assess a 100% tariff on imported ...

President Donald Trump announced Tuesday that imported generic drugs will remain tariff-free for the next two years before facing steep new import duties, saying the move is designed to encourage ...

President Donald Trump on Tuesday announced a plan to impose a 100 percent tariff on generic drugs starting in August 2028 as part of a bid to push pharmaceutical production back to the United States.

The Hikma Court correctly held that a generic manufacturer should not be liable for induced patent infringement if it carves patented uses out of its label. FDA can navigate Hikma’s aftermath without ...